Inflammatory breast cancer (IBC), which involves diffuse tumor cells migrating throughout the breast instead of a mass, skin invasion, and treatment resistance, is rare but accounts for approximately 10% of breast cancer mortality. Despite the name, these clinical signs are caused by blockage of lymphatic channels and skin invasion, not by classic inflammation. Unfortunately, most IBC xenograft models fail to re-capitulate the clinical phenotype of skin invasion and diffuse local spread, a significant limitatin to understanding IBC. In addition, numerous patient tissue studies comparing IBC and non-IBC tumor cells have failed to identify robust genomic or expression differences that drive this unique presentation. Interestingly, our preliminary studies of non-tumor breast tissue >5cm from tumor in IBC and non-IBC patients (i.e., normal adjacent tissue, the """"""""field"""""""") have identified significant differences in macrophage infiltration (increased) and breast stem cell distribution (dispersed) in IBC normal breast tissue. Importantly, in two cases for which pre-malignancy biopsies were available, these differences were demonstrated 10 years prior to diagnosis, suggesting altered homeostasis throughout the breast tissue prior to developing cancer. Further, we recently demonstrated that co-injection of IBC tumor cells with mesenchymal stromal cells (MSCs) induced diffuse skin invasion in IBC xenografts. On the basis of findings in apparently normal breast tissue adjacent to IBC tumors, we hypothesize that epidemiology factors including breast feeding and obesity stimulate macrophage, mesenchymal stem cell and breast stem cell (MMS) interactions prior to the initiation of a cancer, and that these interaction create a field effect that ultimately mediates the IBC phenotype. We propose, using organotypic co-cultures, a novel MSC/IBC xenograft that recapitulates the IBC phenotype, and an innovative, erasable multiplexing, hyperspectral immunofluorescence technology, to characterize MMS interactions in IBC in vitro, to determine if these interactions are necessary for the IBC phenotype in mice, and to image these interactions and related signaling in normal breast tissues from IBC patients. This work is significant because IBC, although rare, accounts for 10% of breast cancer deaths. With co- injection of MSCs in IBC animal models, for the first time, MMS interactions can be manipulated in an animal model to evaluate the clinical hallmarks of IBC. We propose to apply a novel imaging strategy to demonstrate these interactions in IBC normal adjacent tissues from patient samples and animal models, representing a highly innovative, translational approach to visualize niches not possible with standard techniques. Identification of the mediator of the IBC phenotype as being pre-malignant change would dramatically impact therapeutic design strategies for this disease and would potentially influence screening and early detection.

Public Health Relevance

Inflammatory breast cancer (IBC), which involves diffuse tumor cells migrating throughout the breast instead of a mass, skin invasion, and treatment resistance, is rare but accounts for approximately 10% of breast cancer mortality. On the basis of findings in apparently normal breast tissue adjacent to IBC tumors, we hypothesize that epidemiology factors including breast feeding and obesity stimulate macrophage, mesenchymal stem cell and breast stem cell (MMS) interactions prior to the initiation of a cancer, and that these interactions create a field effect that ultimately mediates the IBC phenotype. We propose, using organotypic co-cultures, a novel MSC/IBC xenograft that recapitulates the IBC phenotype, and an innovative, erasable multiplexing immunofluorescence technology, to characterize MMS interactions in IBC in vitro, to determine if these interactions are necessary for the IBC phenotype in mice, and to image these interactions and related signaling in normal breast tissues from IBC patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA180061-02S1
Application #
8775916
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Ogunbiyi, Peter
Project Start
2013-09-17
Project End
2017-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Hospitals
DUNS #
City
Houston
State
TX
Country
United States
Zip Code
77030
Wolfe, Adam R; Bambhroliya, Arvind; Reddy, Jay P et al. (2016) MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. Int J Radiat Oncol Biol Phys 95:791-9
Debeb, Bisrat G; Lacerda, Lara; Larson, Richard et al. (2016) Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget 7:28329-39
Atkinson, Rachel L; El-Zein, Randa; Valero, Vicente et al. (2016) Epidemiological risk factors associated with inflammatory breast cancer subtypes. Cancer Causes Control 27:359-66
Wolfe, Adam R; Debeb, Bisrat G; Lacerda, Lara et al. (2015) Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast Cancer Res Treat 154:495-508
Wolfe, Adam R; Atkinson, Rachel L; Reddy, Jay P et al. (2015) High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. Int J Radiat Oncol Biol Phys 91:1072-80
Lacerda, Lara; Debeb, Bisrat G; Smith, Daniel et al. (2015) Mesenchymal stem cells mediate the clinical phenotype of inflammatory breast cancer in a preclinical model. Breast Cancer Res 17:42
Woodward, Wendy A (2015) Inflammatory breast cancer: unique biological and therapeutic considerations. Lancet Oncol 16:e568-76
Woodward, Wendy A (2014) Postmastectomy radiation therapy for inflammatory breast cancer: is more better? Int J Radiat Oncol Biol Phys 89:1004-5
Lacerda, Lara; Reddy, Jay P; Liu, Diane et al. (2014) Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. Stem Cells Transl Med 3:849-56